We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Model for Brain Tumor Classification Advances Neuropathology

By LabMedica International staff writers
Posted on 28 Dec 2023

Diffuse gliomas, which comprise a large portion of malignant brain tumors in adults, include various types such as astrocytoma, oligodendroglioma, and glioblastoma. More...

Diagnosing these types of gliomas traditionally relies on an analysis that integrates histological characteristics with molecular details, a method that presents significant complexities when attempting to develop a comprehensive diagnostic model from whole-slide images (WSIs). The immense gigapixel resolution of WSIs renders the use of standard convolutional neural networks for analysis impractical. To address this challenge, researchers have now introduced a novel integrated diagnostic model that can automatically classify adult-type diffuse gliomas directly from unannotated standard whole-slide pathological images, eliminating the need for additional molecular testing.

Researchers from the Chinese Academy of Sciences (CAS, Beijing, China) have devised this deep learning model capable of parsing WSIs and categorizing gliomas without the need for detailed manual annotations. This model adheres to the strict classification guidelines outlined in the 2021 fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System. The model underwent training and validation across a diverse dataset comprising 2,624 patient cases collected from three different hospitals.

The model's effectiveness was evaluated based on its classification accuracy, sensitivity to various glioma types and grades, and its capability to differentiate between genotypes that exhibit similar histological characteristics. The outcomes of the experiments indicate that the model demonstrates robust performance, with all areas under the receiver operator curve exceeding 0.90. This performance was noted in its ability to classify major tumor types, identify tumor grades within each type, and, notably, distinguish between tumor genotypes that share the same histological features.

"Our integrated diagnosis model has the potential to be used in clinical scenarios for automated and unbiased classification of adult-type diffuse gliomas," said CAS Prof. Li Zhicheng who led the research team. "The future research will focus on improving this model to have multi-center, multi-racial datasets."

Related Links:
Chinese Academy of Sciences


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.